Efficacy and safety of celecoxib in schizophrenia: a systematic review and meta-analysis of randomized controlled trials.

ABSTRACT:

Background

The hypothesis of immune and inflammatory dysregulation has been supported in the pathogenesis of schizophrenia; this systematic review and meta-analysis aims to evaluate the efficacy and safety of celecoxib, which is a COX-2 inhibitor with anti-inflammatory effects, in the management of schizophrenia.

Methods

A comprehensive search of electronic databases, including PubMed, Scopus, Cochrane, and Web of Science, was performed in February 2025. We included only randomized controlled trials (RCTs) comparing celecoxib alone or as an adjunct to antipsychotics to placebo. Risk of bias was assessed using the ROB-2 tool, and the data of included studies were extracted and analyzed using RevMan 5.4 software. The primary outcome was the change in PANSS (Positive and Negati

SUBMITTER: Farag N 

PROVIDER: S-EPMC12443880 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature